Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial

Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial

To evaluate the safety of the 15-valent pneumococcal conjugate vaccine (PCV15 (by LvZhu & Co. Ltd)) in healthy infants aged 2 months (minimum to 6 weeks) and 3 months old. This phase I clinical trial enrolled 80 subjects in Laishui County, Hebei Province, China. The total population was divided...

Full description

Bibliographic Details
Main Authors:	Lu-Lu Pan, Zhao Gao, Wei-Wei Zhou, Min-Jie Li, Wen-Jian Fang, Wen-Juan Ji, Ying Zhao, Lin Du, Yu-Liang Zhao
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-11-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	pneumococcal 15-valent conjugate vaccine safety phase i clinical trial
Online Access:	http://dx.doi.org/10.1080/21645515.2022.2116881

Similar Items

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019-03-01)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023-09-01)

A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants
by: Yasunori Ishihara, et al.
Published: (2024-04-01)

Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial
by: Jonghoon Shin, et al.
Published: (2020-07-01)

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial
by: Bhagirath B. Solanki, et al.
Published: (2017-09-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
by: Anna M.M. van Deursen, et al.
Published: (2012-11-01)

A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
by: Soon Min Lee, et al.
Published: (2018-12-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
by: Helen L. Stacey, et al.
Published: (2019-03-01)

Safety of simultaneous vaccination of 13-valent pneumococcal polysaccharide conjugate vaccine with other vaccines in Shanghai from 2017 to 2021
by: YANG Shoufei, et al.
Published: (2022-08-01)

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study
by: Miwa Haranaka, et al.
Published: (2023-08-01)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
by: Charu Sabharwal, et al.
Published: (2022-11-01)

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial
by: Wenjuan Wang, et al.
Published: (2022-01-01)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
by: Ching-Fen Shen, et al.
Published: (2021-09-01)

Changes in Childhood Pneumonia Hospitalizations by Race and Sex Associated with Pneumococcal Conjugate Vaccines
by: Andrew D. Wiese, et al.
Published: (2016-06-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023-06-01)

Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations
by: Christine Juergens, et al.
Published: (2018-08-01)

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
by: Strutton David R, et al.
Published: (2012-08-01)

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020-01-01)

A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants
by: R. Rupp, et al.
Published: (2019-03-01)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019-03-01)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
by: Hyunju Lee, et al.
Published: (2014-02-01)

Clinical and Bacteriological Analysis of Pediatric Pneumococcal Meningitis after 13-Valent Pneumococcal Conjugate Vaccine Introduction in Japan
by: Erika Kurihara, et al.
Published: (2022-04-01)

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly
by: Lili Huang, et al.
Published: (2019-01-01)

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine
by: Estelle Méroc, et al.
Published: (2023-07-01)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
by: Yaru Shi, et al.
Published: (2023-08-01)

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
by: John M. McLaughlin, et al.
Published: (2019-04-01)

Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers
by: L A Shpagina, et al.
Published: (2018-11-01)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
by: Michael W. Simon, et al.
Published: (2023-08-01)

Estimated public health impact of nationwide vaccination of infants with 7-valent pneumococcal conjugate vaccine (PCV7) in China
by: ShanLian Hu, et al.
Published: (2014-09-01)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024-12-01)

Empyema due to Streptococcus Pneumoniae Serotype 9V in a Child Immunized with 13-Valent Conjugated Pneumococcal Vaccine
by: Murat Sütçü, et al.
Published: (2017-02-01)

Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
by: Pasiarski M, et al.
Published: (2019-10-01)

Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China
by: Caixia Wang, et al.
Published: (2021-07-01)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
by: Yu Hu, et al.
Published: (2022-01-01)

Vaccine effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: a systematic search and meta-analysis
by: Melina Gade Sikjær, et al.
Published: (2023-01-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
by: Earnshaw Stephanie R, et al.
Published: (2012-04-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)